Patent classifications
A61K9/70
Methods and compositions for wound healing
The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.
Process for producing an oxidized nanofibrillar cellulose hydrogel
A process for producing an oxidized nanofibrillar cellulose hydrogel is disclosed, wherein the process comprises oxidizing cellulose pulp fibers in the presence of hypochlorite as an oxidant and a heterocyclic nitroxyl radical as a catalyst; and disintegrating the oxidized cellulose pulp fibers to obtain a nanofibrillar cellulose hydrogel; wherein all steps of the process after oxidizing are performed under aseptic conditions. An oxidized nanofibrillar cellulose hydrogel and a system for producing the same are also disclosed.
Process for producing an oxidized nanofibrillar cellulose hydrogel
A process for producing an oxidized nanofibrillar cellulose hydrogel is disclosed, wherein the process comprises oxidizing cellulose pulp fibers in the presence of hypochlorite as an oxidant and a heterocyclic nitroxyl radical as a catalyst; and disintegrating the oxidized cellulose pulp fibers to obtain a nanofibrillar cellulose hydrogel; wherein all steps of the process after oxidizing are performed under aseptic conditions. An oxidized nanofibrillar cellulose hydrogel and a system for producing the same are also disclosed.
GRAPHENE BIOSCAFFOLDS AND THEIR USE IN CELLULAR THERAPY
A bioscaffold comprising a graphene matrix for use in cellular therapy is disclosed. In particular, a bioscaffold having a coating of dexamethasone on a three-dimensional graphene matrix is provided, wherein the bioscaffold elutes dexamethasone to reduce inflammatory responses following implantation of the bioscaffold in a subject. Having the dexamethasone released locally in the vicinity of the bioscaffold avoids the systemic side effects from conventional intravenous delivery while allowing the dexamethasone to modulate the inflammatory milieu within the transplantation microenvironment.
Asenapine-containing adhesive patch
An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.
Compositions and methods for treating acne vulgaris
Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.
SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING VALENTONIN AND USE THEREOF AS A MEDICAMENT
The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).
PREVENTION AND TREATMENT OF ITCH WITH AN MRGPR ANTAGONIST
Embodiments described herein relates to compositions and methods of preventing and/or treating itch in a subject using a therapeutically effective amount of a MRG receptor antagonist. e.g., a tripeptide QWF. In one embodiment, the itch is a non-histamine mediated itch.
MULTI-PHASE SILICONE ACRYLIC HYBRID VISCO-ELASTIC COMPOSITIONS AND METHODS OF MAKING SAME
A multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, removing the first solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition. Alternatively, a multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, adding a processing solvent having a higher boiling point than the first solvent, applying heat to selectively remove a majority of the first solvent, removing the processing solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition. The phase arrangement of the multi-phase silicone acrylic hybrid visco-elastic compositions is selectively controlled by selection of the second solvent.